Aclarion, Inc. reported its financial results for the quarter ended March 31, 2024, with a revenue of $10,114, a decrease from the previous year's $25,470. The company experienced a gross loss of $9,362 compared to a gross profit of $8,017 in the same quarter of the previous year. Operating expenses totaled $1,265,945, with sales and marketing at $181,056, research and development at $239,042, and general and administrative expenses at $845,847. The net loss for the quarter was $2,399,102, a larger loss than the $1,183,460 reported in the same period last year. The company completed a public offering, raising approximately $3.0 million before expenses, and also raised about $1.4 million from an equity line. As of March 31, 2024, Aclarion had cash, including restricted cash, of $2,142,635. The company's management believes that current funds will be sufficient to support operations into the third quarter of 2024. Aclarion is focused on leveraging magnetic resonance spectroscopy (MRS) and a proprietary biomarker to optimize clinical treatments. The company is also working on improving its internal control over financial reporting and addressing material weaknesses identified in its disclosure controls and procedures.

Aclarion, Inc. reported its financial results for the quarter ended March 31, 2024, with a revenue of $10,114, a decrease from the previous year's $25,470. The company experienced a gross loss of $9,362 compared to a gross profit of $8,017 in the same quarter of the previous year. Operating expenses totaled $1,265,945, with sales and marketing at $181,056, research and development at $239,042, and general and administrative expenses at $845,847. The net loss for the quarter was $2,399,102, a larger loss than the $1,183,460 reported in the same period last year. The company completed a public offering, raising approximately $3.0 million before expenses, and also raised about $1.4 million from an equity line. As of March 31, 2024, Aclarion had cash, including restricted cash, of $2,142,635. The company's management believes that current funds will be sufficient to support operations into the third quarter of 2024. Aclarion is focused on leveraging magnetic resonance spectroscopy (MRS) and a proprietary biomarker to optimize clinical treatments. The company is also working on improving its internal control over financial reporting and addressing material weaknesses identified in its disclosure controls and procedures.